Jun 10 |
InMed to Present at the Emerging Growth Conference
|
Jun 6 |
Why Smartsheet Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket
|
May 14 |
InMed Pharmaceuticals GAAP EPS of -$0.18, revenue of $1.17M
|
May 14 |
InMed Pharmaceuticals Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update
|
Apr 18 |
InMed Appoints Dr. David G. Morgan, PhD, a Leading Alzheimer's Expert, to the Company's Scientific Advisory Board
|
Apr 16 |
InMed Provides Update on INM-089 in the Treatment of Dry Age-Related Macular Degeneration
|
Apr 4 |
InMed's INM-901 Demonstrates Favorable Pharmacological and Behavioral Effects in In Vivo Preclinical Alzheimer's Disease Studies
|
Mar 20 |
InMed Pharmaceuticals gets 180-Day extension to regain compliance with Nasdaq
|
Mar 20 |
InMed Granted 180-Day Extension to Achieve Nasdaq Minimum Bid Compliance
|
Feb 23 |
InMed Pharmaceuticals And 2 Other Penny Stocks Insiders Are Buying
|